pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Oclaiz
drug · protein
save

octreotide LA

pre_registrationupdated 3mo ago
by Camurus AB🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 7
  • drugoctreotide acetate4 co-mentions · 4 sources
  • drugoctreotide acetate DR4 co-mentions · 4 sources
  • drugoctreotide acetate LA4 co-mentions · 4 sources
  • drugBynfezia4 co-mentions · 4 sources
  • companyTeva Pharmaceuticals USA Inc3 co-mentions · 3 sources
  • tagRecall3 co-mentions · 3 sources
  • tagApproval2 co-mentions · 1 sources

Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for acromegaly and 25 investigational indications.

targets

Somatostatin receptor

all catalysts(0)

nothing on the calendar yet

Trials studying octreotide LA

  • —An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegalynot yet recruitingn=200
  • phase3An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.recruitingn=220
  • phase3Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumorsrecruitingn=298
  • phase3Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NETrecruitingn=240
  • phase3Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapyrecruitingn=338
  • phase3Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NETactive not recruitingn=226
  • phase3A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegalycompletedn=135
  • phase3A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NETactive not recruitingn=332
more trials →

News(0)

no news has mentioned this drug yet

brand
Oclaiz
generic
octreotide
MOA
Somatostatin receptor agonist
indication
Acromegaly
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 59m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?